#16
|
|||
|
|||
Âñå ñ Âàìè ïîíÿòíî
![]() |
#17
|
|||
|
|||
Èíòåðåñíàÿ èíôîðìàöèÿ ê íàøåìó îáñóæäåíèþ. Ñëó÷àé åäèíè÷íûé è, âîçìîæíî, íå ñâÿçàííûé ñ òðåòèíîèíîì, íî òåì íå ìåíåå.
Topical Tretinoin and Neurologic Side Effects This report describes a surprising association between topical tretinoin and neurotoxicity. A 39-year-old woman presented with complaints of headache, memory loss, and unsteadiness that interfered with simple daily activities. Examination showed truncal ataxia and dysarthria. The patient was suffering from untreated depression and chronic hepatitis C. Her liver enzymes were elevated by 30%, consistent with mild hepatitis, but her EEG was normal. The cause of the neurologic disease was unclear until the patient revealed that she had borrowed a friend's topical tretinoin (0.025%) to treat her own acne about four to six weeks before she visited the neurologist. She had been using large amounts of cream and developed dermatitis on her face. Two weeks after she stopped using the cream, her neurologic problems improved but her acne worsened. When she restarted the cream, the ataxia returned. The ataxia cleared four weeks after she again stopped using the cream, and she remained well for eight months. Her liver tests were unchanged. The authors speculate that tretinoin was the cause of the neurotoxicity, since vitamin A and synthetic retinoids can cause headache, pseudotumor cerebri, irritability, ataxia, fatigue, depression, and psychosis. Factors that may have put this patient at risk are increased absorption of the retinoid through her inflamed, excoriated skin and increased availability of the retinoid because of reduced production of retinol-binding protein due to liver disease. Comment: Topical tretinoin has been on the market for 24 years. This isolated report suggests that many susceptibility factors must be present for neurotoxicity to occur. These include high dose, breakdown of the skin barrier, and liver disease. I think it likely that other, unknown co-factors must also be present. Nevertheless, we need to be cautious when using topical retinoids in patients with liver disease and to warn them about possible neurotoxicity. — NH Shear Published in Journal Watch Dermatology March 1, 1996 Citation(s): Bernstein AL; Leventhal-Rochon JL. Neurotoxicity related to the use of topical tretinoin (Retin-A). Ann Intern Med 1996 124 227-228. |
#18
|
|||
|
|||
Ïîëíàÿ ñòàòüÿ.
Neurotoxicity Related to the Use of Topical Tretinoin (Retin-A) Allan L. Bernstein, MD; and Jeanne L. Leventhal-Rochon, MD + Author Affiliations From the Kaiser Permanente Medical Center, Hayward, California. Acknowledgments: The authors thank Hemmige Bhagavan, PhD, Hoffmann-La Roche, Inc., Nutley, New Jersey, for reviewing the manuscript and for providing helpful suggestions, and the Medical Editing Department, Kaiser Foundation Research Institute, for editorial assistance. Requests for Reprints: Allan L. Bernstein, MD, Department of Neurology, Kaiser Permanente Medical Center, 401 Bicentennial Way, Santa Rosa, CA 95403-2192. Topical tretinoin (Retin-A, Ortho, Raritan, New Jersey), a vitamin A analog, has been used to treat acne vulgaris since 1972 in the United States. Oral [1], but not topical [2], forms of vitamin A have been associated with neurologic complications, and systemic absorption through intact skin is minimal [3]. The package insert of topical tretinoin includes no warning about neurotoxicity [4]. We report a case of neurologic and psychiatric symptoms that resolved after use of topical tretinoin was discontinued. Next SectionCase Report A 39-year-old woman was healthy except for mild, untreated depression and chronic hepatitis C. She had used topical tretinoin (Retin-A cream, 0.025% tretinoin) for treatment of acne 6 to 8 weeks before visiting the neurology department. The medication was not prescribed by a physician but rather was “borrowed” from a friend. Although the medication caused itching, she continued using it, often excoriating her skin by scratching. The patient reported headache, memory loss, and unsteadiness that interfered with walking, driving, and working. Medical evaluation 4 weeks after she began using topical tretinoin showed truncal ataxia and dysarthria. The only medication she admitted using was cyclobenzaprine hydrochloride (10 mg, 1 tablet 2 to 4 times weekly), which she stated she took only occasionally. Symptoms increased during the next 2 weeks. Neurologic examination showed mild dysarthria, finger-to-nose ataxia, truncal ataxia requiring the use of a walker, normal deep-tendon reflexes, and normal cranial nerves. Motor and sensory test results were normal. Mental status examination showed anxiety and depression that had worsened during the previous 6 weeks. Brain magnetic resonance imaging yielded normal results. Alanine and aspartate aminotransferase levels were 25% to 30% above normal, consistent with hepatic disease, but had been at similar levels for the previous 5 years. Electroencephalographic results were normal. The patient initially received doxepin hydrochloride, 30 mg daily for 2 weeks. Despite temporary improvement, symptoms recurred 6 weeks later, including worsening dysarthria. After toxic encephalopathy and depression were diagnosed at psychiatric evaluation, we attempted to identify any exposure to a potentially neurotoxic chemical. The patient then mentioned that she had been using large amounts of topical tretinoin during the 6 to 8 weeks before her first visit to the neurology department. Topical tretinoin use was discontinued for 4 weeks but was restarted when acne worsened. The transient improvement in ataxia, dysarthria, and headache that occurred 2 weeks after the patient's first visit to the neurology department corresponded with discontinuation of this medication. However, resumed use of topical tretinoin was associated with a recurrence of the patient's symptoms. Topical tretinoin use was again discontinued, and symptoms resolved within 4 weeks. After 8 months, symptoms had not recurred. Liver function test results have not changed. Previous SectionNext SectionDiscussion Topical tretinoin, or all-trans retinoic acid, is a synthetic retinoid that also occurs naturally and may be a normal metabolite of vitamin A. The degree of topical tretinoin absorption through intact skin is reported to be less than 5% [3]. Extensive clinical experience has not identified a specific neurologic toxicity resulting from the use of this form of retinoic acid. Neurotoxicity of vitamin A and synthetic retinoids resulting from use of oral forms of these medications has been described; symptoms include headache, pseudotumor cerebri, irritability, ataxia, fatigue, depression, and psychosis [5-9]. Vitamin A is readily available in Western diets. It is found as retinyl esters or provitamin A (carotenoids) [5]. The compounds pass through the lumen of the gut after being converted to retinol by pancreatic lipases and re-esterified in the mucosal cells and are transported by chylomicrons in the lymphatic system to the systemic circulation. The retinol is then taken up by the liver for storage and later release. Retinol is bound to retinol-binding protein for release in the circulation [10]. Preexisting liver injury may impair the ability of the liver to produce retinol-binding protein and may limit the effectiveness of transport mechanisms [11]. In addition, high concentrations of vitamin A may be toxic to the liver, eventually producing cirrhosis [12, 13]. Therefore, long-term exposure to high doses of vitamin A or preexisting injury to the liver or both may result in high concentrations of unbound retinol, which may be physiologically unavailable to vitamin A-dependent target tissues and which may also produce additional hepatotoxicity [14] as well as neurotoxicity [15]. Retinoic acid may produce the neurotoxic symptoms of hypervitaminosis A in patients with preexisting hepatic dysfunction [14]. Inability to conjugate retinoic acid to an excretable form or to produce retinol-binding proteins may contribute to toxicity [14]. Because our patient did not consider her topical medication to be a drug and because it was supplied by a friend, review of her medical records failed to identify topical tretinoin as a potential cause of her symptoms. Physicians should use caution in prescribing topical retinoids for patients who have known or potential hepatic dysfunction. Copyright ©2004 by the American College of Physicians Previous Section References 1.↵Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL. Evaluation of vitamin A toxicity. Am J Clin Nutr. 1990; 52:183-202. 2.↵Chren M, Bickers DR. Dermatological pharmacology. In: Goodman LS, Gilman A, Gilman AG, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 8th ed. New York: Pergamon Pr; 1990:1572-91. 3.↵Marcus R, Coulston AM. Fat-soluble vitamins. In: Goodman LS, Gilman A, Gilman AG, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 8th ed. New York: Pergamon Pr; 1990:1553-71. 4.↵Ortho Pharmaceutical Corporation. Dermatological Division. Retin-A (tretinoin) [package insert]. Raritan, NJ: Ortho Pharmaceutical; 1990 (revised November 1992). 5.↵Biesalski HK. Comparative assessment of the toxicology of vitamin A and retinoids in man. Toxicology. 1989; 57:117-61. 6.↵Bendich A, Langseth L. Safety of vitamin A. Am J Clin Nutr. 1989; 49:358-71. 7.↵Moskowitz Y, Leidowitz E, Ronen M, Aviel E. Pseudotumor cerebri induced by vitamin A combined with minocycline. Ann Opthalmol. 1993; 25:306-8. 8.↵Restak RM. Pseudotumor cerebri, psychosis, and hypervitaminosis A. J Nerv Ment Dis. 1972; 155:72-5. 9.↵Spector RH, Carlisle J. Pseudotumor cerebri caused by a synthetic vitamin A preparation. Neurology. 1984; 34:1509-11. 10.↵Snodgrass SR. Vitamin neurotoxicity. Mol Neurobiol. 1992; 6:41-73. 11.↵Smith FR, Goodman DS. Vitamin A transport in human vitamin A toxicity. N Engl J Med. 1976; 294:805-8. 12.↵Geubel A, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991; 100:1701-9. 13.↵Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol. 1992; 27(6 pt 2):S29-S33. 14.↵Hatoff DE, Gertler SL, Miyai K, Parker BA, Weiss JB. Hypervitaminosis A unmasked by acute viral hepatitis. Gastroenterology. 1982; 82:124-8. 15.↵Bigby M, Stern RS. Adverse reactions to isotretinoin: a report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol. 1988; 18:543-52. |
#19
|
|||
|
|||
Ïîæàëóé, ýòîò âîïðîñ íóæíî áûëî çàäàòü â ñàìîì íà÷àëå íàøåãî îáùåíèÿ.
×òî æå ìîæåò áûòü ïðè÷èíîé òàêîãî äëèòåëüíîãî è âûðàæåííîãî òå÷åíèÿ ñåáîðåè? 7 ëåò ïðàêòè÷åñêè áåç óëó÷øåíèÿ. Âîâëå÷åíû: íîãè, ðóêè îò çàïÿñòüÿ äî ïëå÷à, ïëå÷è, âñÿ ñïèíà, ãðóäü, æèâîò, áîêà, øåÿ, âñå ëèöî, âîëîñèñòàÿ ÷àñòü ãîëîâû. Âîñïàëåíèÿ íå ñèëüíûå (õîòÿ áûâàþò è èñêëþ÷åíèÿ), íî â êàæäîé ïîðå êîìåäîí, ïåðåðîæäåíèå âîëîñÿíûõ ôîëëèêóëîâ, òåíäåíöèÿ ê âñå áîëåå ÷àñòîìó îáðàçîâàíèþ çàêðûòûõ êîìåäîíîâ. Î÷åíü ñèëüíîå ñàëîîòäåëåíèå íà ëèöå. Âîëîñû æèðíÿòñÿ ìåíüøå ÷åì çà ñóòêè. Ñòàëè àêòèâíåå âûïàäàòü. Òî åñòü ãëàâíàÿ ïðîáëåìà èìåííî âûðàæåííîå íàðóøåíèå ñàëîîòäåëåíèÿ. ×òî Âû ìîæåòå ïîñîâåòîâàòü ïîìèìî ðåòèíîèäîâ? ×åì ìûòü ãîëîâó? ×òî äåëàòü ñ òåëîì? Íà òåëå áîëüøîå êîëè÷åñòâî ðóáöîâ (âûïóêëûõ) èìååò ëè ñìûñë èñïîëüçîâàòü ôðóêòîâûå êèñëîòû èëè ÷òî–òî â ýòîì ðîäå? ×èòàë â Âàøåì ïðîôèëå, ÷òî Âû ïðîõîäèëè ñòàæèðîâêó çà ãðàíèöåé, è, íàäåþñü, ÷òî íå ïîëó÷ó îò âàñ ñîâåòîâ âðîäå îãðàíè÷åíèÿ îñòðîãî, æèðíîãî, ñëàäêîãî, èëè àóòîãåìîòåðàïèè, èëè íîðìàëèçàöèè ðåæèìà òðóäà è îòäûõà? ![]() ![]() ß äåéñòâèòåëüíî ïåðåðûë ãîðû ëèòåðàòóðû, è, âîîáùå òî, íå çíàþ, íà ÷òî ÿ íàäåþñü, çàäàâàÿ âñå ýòè âîïðîñû, íî âäðóã ÿ ÷òî–òî ïðîïóñòèë? ß æå íå äèïëîìèðîâàííûé âðà÷. Äà è íàäåæäà, êàê èçâåñòíî, ïðåêðàñíîå ÷óâñòâî ![]() Ñ óâàæåíèåì Ìàêñèì |
#20
|
|||
|
|||
Öèòàòà:
Öèòàòà:
- ñåáîðåÿ-åñòü íîðìà, êîñìåòè÷åñêèé óõîä ïîçâîëÿåò ñäåëàòü êîìôîðòíûì, - ýòî îñíîâíàÿ öåëü, à ÷òî ñ óõîäîì? ìîæíî îáðàòèòüñÿ ê êîíñóëüòàíòó â àïòåêå èëè ê êîñìåòîëîãó, â íàøå âðåìÿ ýòî âîçìîæíî - ðåòèíîèäû ïðèìåíÿþòñÿ äàëåêî íå â êàæäîì ñëó÷àå ñåáîðåè-ýòî ñîâìåñòíîå ðåøåíèå è ïîä êîíòðîëåì âðà÷à - Âû î÷íî îáðàùàëèñü? ê äåðìàòîëîãó è êîñìåòîëîãó(óõîä)?-ýòî Âàì ïîòðåáóåòñÿ, ÷åðåç Èíòåðíåò Âàøå ëþáîïûòñòâî ìû íå óäîâëåòâîðèì Öèòàòà:
|
#21
|
|||
|
|||
Óâàæàåìàÿ Ìàðèÿ Þðüåâíà!
Çà 7 ëåò ñåáîðåè ÿ îáîøåë ïðàêòè÷åñêè âñåõ äåðìàòîëîãîâ Êèåâà. Óâåðÿþ Âàñ, óðîâåíü óêðàèíñêîé ìåäèöèíû íèæå ïëèíòóñà. Ïðè ÆÈÐÍÎÉ ÑÅÁÎÐÅÅ âðà÷è ñîâåòóþò çàãîðàòü, è ïðîïèñûâàþò ñïèðòîâûå áîëòàíêè! Ýòî æå àáñóðä! Èíñîëÿöèÿ è ñïèðò â çíà÷èòåëüíîé ñòåïåíè óñóãóáëÿþò êàðòèíó òå÷åíèÿ áîëåçíè! Î Áàçèðîíå çäåñü íèêòî íå ñëûøàë, òàêæå êàê è î ìåñòíîì Òðåòèíîèíå. Ïî êðàéíåé ìåðå, åùå äâà ãîäà íàçàä ñèòóàöèÿ áûëà òàêîâîé. ß î÷åíü ïðîøó Âàñ! Ïåðå÷èòàéòå åùå ðàç ìîå ïðåäûäóùåå ïèñüìî. ×òî áû Âû âñå-òàêè ïîñîâåòîâàëè? Àíàëèçû, ñõåìà ëå÷åíèÿ. Ñàëîîòäåëåíèå, ðóáöû. Ðàñïðîñòðàíåííîñòü ïðîöåññà. Íåóæåëè Âû äóìàåòå, ÷òî ìíå, ìóæ÷èíå, ëåãêî îá ýòîì ïèñàòü? Ïðîñòî ìíå áîëüøå íå ê êîìó îáðàòèòñÿ. Ìîãó âûñëàòü ôîòîãðàôèþ, ðåçóëüòàòû ðàçëè÷íûõ îáñëåäîâàíèé. Ñ íàèëó÷øèìè ïîæåëàíèÿìè Ìàêñèì |
#22
|
|||
|
|||
- êàêîé äèàãíîç? ýòî ñïåöèàëèñòû äîëæíû áûëè îïðåäåëèòü, ðå÷ü òîëüêî î ñåáîðåå ëè?
Öèòàòà:
http://forums.rusmedserv.com/showthread.php?t=94701 - îïèøèòå ïîäðîáíî ñèòóàöèþ+ññûëêè íà ôîòî: "Êàê ëó÷øå ñîçäàòü ñâîé âîïðîñ-ñîîáùåíèå" http://forums.rusmedserv.com/showpos...43&postcount=2 - ðå÷ü íà ïåðâîì ìåñòå íå î ëå÷åíèè ñåáîðåè, àî ïðàâèëüíîì ëå÷åíèè àêíå, âîò â ÷åì ðàçíèöà, à Âû áîëüøå íà ñåáîðåå àêöåíòèðóåòåñü(ñåáîðåÿ òðåáóåò òîëüêî êîñìåòè÷åñêîãî óõîäà â áîëüøèíñòâå ñëó÷àåâ), à àêíå òðåáóåò ëå÷åíèå ñîãëàñíî êëèíè÷åñêèì ïðîÿâëåíèÿì-ôîðìå êëèíè÷åñêîé è ñòåïåíè òÿæåñòè-âñÿ èíôîðìàöèÿ ïî ëå÷åíèþ åñòü â ×àÂî |
|
#23
|
|||
|
|||
Óâàæàåìàÿ Ìàðèÿ Þðüåâíà!
Äèàãíîç: æèðíàÿ ñåáîðåÿ, âóëüãàðíûå óãðè, ôîëëèêóëèò? Ñòàâèëñÿ íåîäíîêðàòíî ðàçíûìè äåðìàòîëîãàìè. ß ïîçâîëþ ñåáå Âàñ ïîïðàâèòü. Ñåáîðåÿ íå ïðåäðàñïîëàãàþùèé ôàêòîð. Ïðåäðàñïîëàãàþùèìè ôàêòîðàìè ìîãóò áûòü ïîâûøåííûå àáñîëþòíûå êîíöåíòðàöèè ïîëîâûõ ãîðìîíîâ â êðîâè, ÷óâñòâèòåëüíîñòü ðåöåïòîðîâ ê äàííûì àãåíòàì, íåñîñòîÿòåëüíîñòü ðàáîòû ïå÷åíè è ò.ä. Íî ñåáîðåÿ, ò.å íàðóøåíèå ôóíêöèè ñàëüíûõ æåëåç, è åñòü îñíîâíîå íåáëàãîïîëó÷èå. Àêíå âåðøèíà àéñáåðãà. Ñîãëàñíû ëè Âû, ÷òî: Ñîâîêóïíîñòü ôàêòîðîâ -> íàðóøåíèå Ô. ñàëüíûõ æåëåç -> îáðàçîâàíèå êîìåäîíîâ ->âîñïàëåíèå -> ðóáöåâàíèå?  áëèæàéøåå âðåìÿ îïèøó êëèíè÷åñêóþ êàðòèíó ïîäðîáíåå. È ñäåëàþ ôîòî. Ñïàñèáî, ÷òî îòêëèêíóëèñü. Ìàêñèì |
#24
|
|||||
|
|||||
Öèòàòà:
Öèòàòà:
![]() - ïðåäðàñïîëàãàþùèé ôàêòîð îòëè÷àåòñÿ òåì, ÷òî, ñàì ïî ñåáå-íå áîëåçíü, â áîëüøèíñòâå ñëó÷àåâ ëå÷åíèÿ íå òðåáóåò, íî ìîæåò ñïîñîáñòâîâàòü â ñîâîêóïíîñòè ñ äðóãèìè ôàêòîðàìè ê àêíå, ñåáîðåéíîìó äåðìàòèòó-ýòî óæå çàáîëåâàíèÿ, ò.å. â òîì è îòëè÷èå ïðåäðàñïîëàãàþùåãî ôàêòîðà, ÷òî îí ìîæåò ïðåäðàñïîëàãàòü ê íåñêîëüêèì çàáîëåâàíèÿì, à ðàçâèòèå áîëåçíè çàâèñèò óæå è îò äðóãèõ ôàêòîðîâ(ãðèáîê, áëàãîïðèÿòíûå óñëîâèÿ äëÿ ìàëàññåçèè, +ñåáîðåÿ=óæå ñåáîðåéíûé äåðìàòèò) - ïðåäðàñïîëàãàþùèé ôàêòîð ìîæåò áûòü îäíîâðåìåííî è ïàòîãåíåòè÷åñêèì, ò.å. âíîñèòü ñâîþ ëåïòó â çàáîëåâàíèå, íî èçîëèðîâàííî áåç ÷óâñòâèòåëüíîñòè ðåöåïòîðîâ ê àíäðîãåíàì, â ïðèíöèïå, ãåíåòè÷åñêîé ïðåäðàñïîëîæåííîñòè, áåç ïðîïèîíåáàêòðèè àêíå, áåç ôîëëèêóëÿðíîãî êåðàòîçà è äð., íå ñîñòàâëÿåò áîëåçíü Öèòàòà:
![]() [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - ëå÷åíèå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - ñåáîðåÿ ÿâëÿåòñÿ òàêèì æå ïðåäðàñïîëàãàþùèì ôàêòîðîì êàê àíäðîãåíû(íå ñòîëüêî èõ àáñîëþòíûé óðîâåíü, à ñêîëüêî ÷óâñòâèòåëüíîñòü ðåöåïòîðîâ), òàêæå êàê íàëè÷èå ïðîïèîíåáàêòåðèè àêíå, òàêæå êàê âñå ïåðå÷èñëåííûå íèæå ôàêòîðû(ôîëëèêóëÿðíûé ãèïåðêåðàòîç) : Öèòàòà:
-èìåþùèìè íàó÷íîå ïîäòâåðæäåíèå ôàêòàìè íà äàííîå âðåìÿ ÿâëÿþòñÿ(ïå÷åíü, ÆÊò è ïðî÷èå âåùè-ïîêà èç îáëàñòè ôàíòàñòèêè) : Öèòàòà:
|
#25
|
|||
|
|||
Äîðîãàÿ Ìàðèÿ Þðüåâíà!
Ñïàñèáî Âàì îãðîìíîå çà òàêîé åìêèé îòâåò! Õîðîøî, ÷òî Âû âñå ýòî íàïèñàëè. Òåïåðü ÿ âèæó, ÷òî ìû ïîíèìàåì äðóã äðóãà. Ïîä ïå÷åíüþ ÿ ïîíèìàþ àêòèâíîñòü ôåðìåíòàòèâíûõ ñèñòåì, êîòîðûå ðàñùåïëÿþò ïîëîâûå ãîðìîíû.  òîì ÷èñëå è ïðåñëîâóòûé äåãèäðîýïèàíäðîñòåðîí. ×èòàë îá ýòîì ìåëüêîì â ñîâðåìåííîé ñòàòüå (ãîëîñëîâåí, ññûëêó äàòü íå ìîãó). Ýòà íå òà "ïå÷åíü", íà êîòîðîé àêöåíòèðîâàëè âíèìàíèå ñîâåòñêèå äåðìàòîëîãè. Ñåáîðåéíûé äåðìàòèò ìíå òîæå ñòàâèëè. Ñåé÷àñ ñ ýòèì ëó÷øå. Äëÿ ìåíÿ äåéñòâèòåëüíî íîâîñòü, ÷òî æèðíàÿ ñåáîðåÿ ìîæåò è íå ïðèâîäèòü ê àêíå. ß ïðèíîøó ñâîè èçâèíåíèÿ. Ñòàòüÿ ó Âàñ çàìå÷àòåëüíàÿ, ïî êðàéíåé ìåðå, íà÷àëî î÷åíü óáåäèòåëüíîå. Ñîñðåäîòî÷åíî âñå òî, ÷òî ÿ ïî êóñî÷êàì ñîáèðàë 7 ëåò. Î÷åíü èíòåðåñíà ÷àñòü, êàñàþùàÿñÿ ëå÷åíèÿ. Æäó. Ñäåëàþ Âàì êîìïëèìåíò - Âû ïðåêðàñíî âëàäååòå ñîâðåìåííîé èíôîðìàöèåé. ß ðàä, ÷òî ìîãó ñ Âàìè îáùàòüñÿ, è íàäåþñü, ÷òî ñìîãó ïðîäâèíóòüñÿ â ëå÷åíèè ñâîåé ïðîáëåìû. Ñ óâàæåíèåì Ìàêñèì |
#26
|
||||
|
||||
Öèòàòà:
- â ëþáîì ñëó÷àå ê ïàòîãåíåçó àêíå ýòî ïðÿìîãî îòíîøåíèÿ íå èìååò(âîçìîæíî â áóäóùåì ÷òî-òî èçìåíèòñÿ), ò.å. äàííûõ, ÷òî çàáîëåâàíèÿ ïå÷åíè èëè ïîêàçàòåëè ôóíêöèè êàê-òî ñâÿçàíû ñ âîçíèêíîâåíèåì è ðàçâèòèåì àêíå, ïîêà íåò, ïî êðàéíåé ìåðå, ïîêà ëå÷åíèå èñõîäèò èç 4 ôàêòîðîâ, ëå÷åíèå "ïå÷åíè" íå òðåáóåòñÿ ïðè àêíå(êîíå÷íî, ìîãóò áûòü çàáîëåâàíèÿ ïå÷åíè êàê ïðîòèâîïîêàçàíèÿ ê ïðèåìó ëåêàðñòâ-ýòî äðóãîå äåëî) Öèòàòà:
![]() - íî äåëî â òîì, ÷òî åñëè â "íàøåì" ïðåäñòàâëåíèè ýòè âèäû ñåáîðåè ðàçäåëÿþòñÿ è êëàññèôèöèðóþòñÿ(ñóõàÿ, æèðíàÿ), òî ýòî âíîñèò çàòðóäíåíèÿ â òîì ñëó÷àå, åñëè åñòü ñåáîðåÿ, ñåá.äåðìàòèò, àêíå,+-ôîëëèêóëèò(ïðèìåðíî êàê â Âàøåì ñëó÷àå)-òîãäà íåò ñìûñëà â ýòîì ðàçäåëåíèè, äà è ïîäõîäû ê ëå÷åíèþ áóäóò ïî ñóòè îäíèìè è òåìè æå-ëå÷èòü ìîæíî àêíå, êîñìåòè÷åñêèé óõîä äëÿ ñåáîðåè, à äëÿ ôîëëèêóëèòà, åñëè îí áàêòåðèàëüíûé-òå æå àíòèáèîòèêè, åñëè îí ìàëàññåçèÿ,-òîãäà êàê äëÿ ñåáîðåéíîãî äåðìàòèòà-êåòîêîíàçîë Öèòàòà:
![]() Öèòàòà:
|
#27
|
|||
|
|||
Óâàæàåìàÿ Ìàðèÿ Þðüåâíà!
Âû ñîâåðøåííî ïðàâû. Ìîé ñëó÷àé ýòî êîìáèíàöèÿ æèðíîé ñåáîðåè, ñåáîðåéíîãî äåðìàòèòà (êîíòàêòíîãî äåðìàòèòà, âûðàæåííûé äåðìîãðàôèçì), àêíå, ñ ïîÿâèâøåéñÿ òåíäåíöèåé ê îáðàçîâàíèþ çàêðûòûõ êîìåäîíîâ, ôîëëèêóëèòà. Ðàñïðîñòðàíåííîñòü âñåîáúåìëþùàÿ. Èç õîðîøåãî - â ïîñëåäíèé ãîä îòìå÷àåòñÿ ïîëîæèòåëüíàÿ äèíàìèêà áåç ìåäèêàìåíòîçíîãî âìåøàòåëüñòâà. Íî äî ïîëíîé ðåìèññèè åùå äàëåêî. Êàê óñòàíîâèòü ïðèðîäó ôîëëèêóëèòà? Ïðè ïîñåâå, â ñâîå âðåìÿ, ó ìåíÿ îáíàðóæèâàëè òîëüêî ýïèäåðìàëüíûé ñòàôèëîêîêê. Êñòàòè, ãîä íàçàä ó ìåíÿ áûë êëàññè÷åñêèé ðîçîâûé ëèøàé. Âïåðâûå â æèçíè. Áëåñòÿùå âûëå÷èë åãî çà 4-5 äíåé Ëàôåðîíîì â âèäå ðåêòàëüíûõ ñâå÷åé (ñîâåò çíàêîìîãî âðà÷à). Ïðè òîì, ÷òî ìåñòíûìè ïðîòèâîãðèáêîâûìè ñðåäñòâàìè (ïðîïèñàë äåðìàòîëîã) ëå÷èëñÿ áåçðåçóëüòàòíî îêîëî ìåñÿöà. Âû ñïðîñèòå: "À ïðè ÷åì òóò ïðîòèâîãðèáêîâûå ñðåäñòâà?". ß òîæå çàäàâàë ñåáå ýòîò âîïðîñ.  áëèæàéøåå âðåìÿ ðàçìåùó ñâîè ôîòîãðàôèè. Áåñêîíå÷íî Âàì ïðèçíàòåëåí. Ìàêñèì |
#28
|
|||
|
|||
Öèòàòà:
Öèòàòà:
- ÷òî ÿâëÿåòñÿ îïðåäåëþùèì êëèíè÷åñêè, ÷òî áîëüøå áåñïîêîèò è èìååò áîëüøèå ïðîÿâëåíèÿ-àêíå èëè ôîëëèêóëèò ïî Âàøåìó/ïî ìíåíèþ ñïåöèàëèñòîâ? - Öèòàòà:
![]() |
#29
|
|||
|
|||
Áåçóñëîâíî, áîëüøå âñåãî áåñïîêîèò àêíå.
Âû äóìàåòå, ÷òî ýòî áûë ýôôåêò ïëàöåáî? |
#30
|
|||
|
|||
Ïî âîçìîæíîñòè, ïåðåâåäèòå ïîæàëóéñòà â ñêðûòûé ðåæèì.
|